טוען...
Integrin antagonists as potential therapeutic options for the treatment of Crohn’s disease
INTRODUCTION: Anti-integrin therapy for the treatment of patients with Crohn’s disease is rapidly evolving. Two agents, natalizumab and vedolizumab, are approved by the United States Food and Drug Administration for the treatment of Crohn’s disease, with vedolizumab the primary anti-integrin used du...
שמור ב:
| הוצא לאור ב: | Expert Opin Investig Drugs |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4926164/ https://ncbi.nlm.nih.gov/pubmed/26822204 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/13543784.2016.1148137 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|